There are currently three types of cervical cancer vaccines: bivalent, quadrivalent and nine-valent vaccines, which differ in the type of prevention and duration of effectiveness. Cervical cancer is the most common gynecological malignancy: due to the increase of women’s awareness of medical checkups and gynecological cervical exfoliation cytology in recent years, the incidence of cervical cancer has been greatly reduced. The introduction of cervical cancer vaccine has undoubtedly brought protection to women. However, the cervical cancer vaccine is effective for about 5-10 years after injection. All three vaccines protect against HPV virus types 16 and 18, which most directly cause cervical cancer. The bivalent vaccine is for women aged 9-25 years and protects against infection by HPV 16 and HPV 18 viruses. The quadrivalent vaccine is indicated for women aged 20-45 years and protects against HPV types 6, 11, 16 and 18 infections. The nine-valent vaccine is for women aged 16-26 years and targets nine subtypes of HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58. The nine-valent vaccine can prevent 90% of cervical cancers. Generally speaking, the cervical cancer vaccine requires three injections in a six-month cycle, with the second injection two months after the first and the third injection in the sixth month. Even with the cervical cancer vaccine, it is important to take precautions. Regular cervical exfoliative cell HPV and TCT examinations are performed annually.